Maarten van der Doelen

Chapter 8

100. Soldatov A, von Klot CAJ, Walacides D, Derlin T, Bengel FM, Ross TL, et al. Patterns of Progression After (68)Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019;103(1):95-104. 101. Hasan H, Deek MP, Phillips R, Hobbs RF, Malek R, Radwan N, et al. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer. 2020;20(1):492. 102. Sartor O, Heinrich D, Mariados N, Mendez Vidal MJ, Keizman D, Thellenberg Karlsson C, et al. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Ann Oncol. 2017;28(10):2464-71. 103. Sartor O, Heinrich D, Mariados N, Mendez Vidal MJ, Keizman D, Thellenberg Karlsson C, et al. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases. Prostate. 2019;79(14):1683-91. 104. Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo controlled, phase 3 trial. Lancet Oncol. 2019;20(3):408-19. 105. Gourd E. EMA guidance on radium-223 dichloride in prostate cancer. Lancet Oncol. 2018;19(4):e190. 106. European Medicines Agency. Xofigo Article-20 procedure. PRAC assessment report. 2018. Available at https://www.ema.europa.eu/medicines/human/referrals/xofigo [ 107. Agarwal N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Gupta S, et al. Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 2020;26(9):2104-10. 108. Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, et al. Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist. 2021;26(12):1006-e2129. 109. McDermott RS, Greene J, McCaffrey J, Parker I, Helanova S, Baird AM, et al. Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi centre, phase II open-label study. Ther Adv Med Oncol. 2021;13:17588359211042691. 110. Shore ND, Schellhammer PF, Tutrone RF, Mariados NF, Harrelson SS. Open Label Phase II Study of EnzalutamideWith Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2020;18(5):416-22. 111. MorrisMJ, LoriotY, SweeneyCJ, Fizazi K, RyanCJ, ShevrinDH, et al. Radium-223 incombination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019;114:107-16. 112. Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. (225)Ac-PSMA-617/(177) Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47(3):721-8.

226